切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2023, Vol. 17 ›› Issue (01) : 50 -54. doi: 10.3877/cma.j.issn.1674-0793.2023.01.010

论著

结直肠癌合并原发性肝癌双原发癌的临床特征分析:附40例报告
陈治平1, 卓宪华2, 俞建东1, 林泽宇1, 李国林1, 万云乐1,()   
  1. 1. 510650 广州,中山大学附属第六医院肝胆胰脾外科;510650 广州,中山大学附属第六医院,广东省结直肠盆底疾病研究重点实验室
    2. 510650 广州,中山大学附属第六医院,广东省结直肠盆底疾病研究重点实验室;510650 广州,中山大学附属第六医院消化内镜科
  • 收稿日期:2022-05-03 出版日期:2023-02-01
  • 通信作者: 万云乐

Characteristics of dual primary carcinoma involving colorectal and hepatic carcinoma: A retrospective analysis of 40 cases

Zhiping Chen1, Xianhua Zhuo2, Jiandong Yu1, Zeyu Lin1, Guolin Li1, Yunle Wan1,()   

  1. 1. Department of Hepatobiliary Surgery, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510650, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510650, China
    2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510650, China; Department of Gastrointestinal Endoscopy, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510650, China
  • Received:2022-05-03 Published:2023-02-01
  • Corresponding author: Yunle Wan
引用本文:

陈治平, 卓宪华, 俞建东, 林泽宇, 李国林, 万云乐. 结直肠癌合并原发性肝癌双原发癌的临床特征分析:附40例报告[J/OL]. 中华普通外科学文献(电子版), 2023, 17(01): 50-54.

Zhiping Chen, Xianhua Zhuo, Jiandong Yu, Zeyu Lin, Guolin Li, Yunle Wan. Characteristics of dual primary carcinoma involving colorectal and hepatic carcinoma: A retrospective analysis of 40 cases[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(01): 50-54.

目的

研究结直肠癌(CRC)合并原发性肝癌(PHC)双原发癌患者的临床病理特征,并分析影响患者预后的危险因素。

方法

回顾性分析2012年7月至2021年6月中山大学附属第六医院40例CRC合并PHC双原发癌患者的临床病理资料,并结合随访资料进行生存分析。

结果

40例中有23例(57.5%)同时性双原发癌和17例(42.5%)异时性双原发癌患者,两组发病年龄和临床病理特征比较,差异无统计学意义。随访14(2~81)个月,31例生存,患者2年生存率为77.6%,5年生存率为61.0%。第一原发癌为CRC的患者(27例)和第一原发癌为PHC的患者(13例)生存时间比较,差异无统计学意义(P=0.346)。第一原发癌种类、发病年龄、发病间隔以及是否存在CRC相关基因突变对患者预后的影响差异无统计学意义。

结论

对于CRC合并PHC双原发癌患者,第一原发癌种类、发病年龄、发病间隔以及是否存在CRC相关基因突变不是影响患者预后的独立危险因素。

Objective

To investigate the clinicopathologic characteristics, treatment modalities, prognosis and risk factors in patients with dual primary carcinoma involving colorectal carcinoma (CRC) combined with primary hepatic carcinoma (PHC).

Methods

The clinicopathologic and follow-up data of 40 cases with dual primary CRC and PHC in the Sixth Affiliated Hospital, Sun Yat-sen University from July 2012 to June 2021 were retrospectively analyzed.

Results

Among the 40 cases, 23 cases (57.5%) were diagnosed with simultaneous dual primary cancer and 17 (42.5%) with metachronous dual primary cancer. There were no significant differences in age of onset and clinicopathological characteristics between the two groups. After 14 months (ranging from 2 to 81 months) of follow-up, 31 cases survived. The 2-, 5-year survival rate was 77.6%, 61.0% respectively. The difference in overall survival between patients with CRC as the first primary cancer (27 cases) and patients with PHC as the first primary cancer (13 cases) was not statistically significant (P=0.346). There were no significant differences in the type of the first primary cancer, age of onset, interval of onset and the presence of CRC-related gene mutation on the prognosis of patients.

Conclusion

For patients with dual primary CRC and PHC, the type of the first primary cancer, age of onset, interval of onset, and the presence of CRC-related gene mutation are not independent risk factors affecting the prognosis of patients.

表1 同时性与异时性双原发癌患者的临床病理特征比较(例)
图1 影响结直肠癌合并原发性肝癌双原发癌患者预后的生存分析 A为第一原发癌种类;B为发病年龄;C为发病间隔;D为是否存在结直肠癌相关基因突变
表2 影响双原发癌患者预后的单因素分析
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]
Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults[J]. Gut, 2019, 68(12): 2179-2185.
[3]
刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J/CD]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13.
[4]
Park YK, Kim DY, Joo JK, et al. Clinicopathological features of gastric carcinoma patients with other primary carcinomas[J]. Langenbecks Arch Surg, 2005, 390(4): 300-305.
[5]
Janpan Soiety for the Study of Obesity (JASSO). Japan Society for the Study of Obesity Guidelines for the management of obesity disease 2016[EB/OL]. (2019-08-01) [2022-05-03].

URL    
[6]
Xu LL, Gu KS. Clinical retrospective analysis of cases with multiple primary malignant neoplasms[J]. Genet Mol Res, 2014, 13(4): 9271-9284.
[7]
Warren S, Gates O. Multiple primary malignant tumors: A survey of the literature and a statistical study[J]. Am J Cancer, 1932, 16: 1358-1414.
[8]
Chen W, Xia C, Zheng R, et al. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: A comparative risk assessment[J]. Lancet Glob Health, 2019, 7(2): e257-257, e269.
[9]
Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3): 145-164.
[10]
国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J/CD]. 中华普通外科学文献(电子版), 2022, 16(2): 81-96.
[11]
中国临床肿瘤学会(CSCO)结直肠癌专家委员会. 结直肠癌分子标志物临床检测中国专家共识[J]. 中华胃肠外科杂志, 2021, 24(3): 191-197.
[12]
Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American society of clinical oncology provisional clinical opinion update 2015[J]. J Clin Oncol, 2016, 34(2): 179-185.
[13]
Dong C, Ding Y, Weng S, et al. Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020[J]. Chin J Cancer Res, 2021, 33(3): 302-307.
[14]
Ye H, Zhang C, Wang BJ, et al. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice[J]. Oncogene, 2014, 33(43): 5133-5138.
[15]
Rose PG, Herterick EE, Boutselis JG, et al. Multiple primary gynecologic neoplasms[J]. Am J Obstet Gynecol, 1987, 157(2): 261-267.
[16]
Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.
[17]
Watanabe M, Kochi M, Fujii M, et al. Dual primary gastric and colorectal cancer: is the prognosis better for synchronous or metachronous?[J]. Am J Clin Oncol, 2012, 35(5): 407-410.
[1] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[2] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[3] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[4] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[5] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[6] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[7] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[8] 林小勇, 张兰霞, 曾庆劲, 贺需旗, 谭雷, 郭光辉, 龙颖琳, 李凯, 吴宇轩. 负压抽吸活检针在肝困难病灶活检中的初步应用研究[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 694-698.
[9] 雷永琪, 刘新阳, 杨黎渝, 铁学宏, 俞星新, 耿志达, 刘雨, 陈政良, 惠鹏, 梁英健. 肝脏血管周上皮样细胞肿瘤合并贫血一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 710-718.
[10] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[11] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[12] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[13] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[14] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[15] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
阅读次数
全文


摘要